Research programme: pain therapeutics - Penwest PharmaceuticalsAlternative Names: Pain therapeutics research programme - Penwest Pharmaceuticals; PW 4102; PW 4104
Latest Information Update: 25 Apr 2007
At a glance
- Originator Penwest Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 25 Apr 2007 Discontinued - Preclinical for Pain in USA (unspecified route)
- 21 Oct 2003 Preclinical trials in Pain in USA (unspecified route)